Pradaxa
Boehringer’s Pradaxa fails to meet Phase 3 endpoint in preventing recurrent stroke
May 20, 2019Research and Development, Sales and Marketing Boehringer, Pradaxa, pharma, stroke, trial failure
Boehringer has announced that Pradaxa (dabigatran etexilate mesylate) has failed to meet its primary endpoint in its Phase 3 study, …
FDA approves Boehringer’s Pradaxa reversal agent
October 19, 2015Sales and Marketing Boehringer Ingelheim, FDA, Pradaxa, Praxbind, anticoagulant, idarucizumab
The FDA has approved Boehringer Ingelheim’s Praxbind, a reversal agent for its anticoagulant Pradaxa. The US regulator approved Praxbind (idarucizumab) …
Boehringer scores trial success for Pradaxa antidote
June 29, 2015Research and Development, Sales and Marketing Boehringer, Pradaxa, idarucizumab
Bosses at Boehringer Ingelheim say the latest results of a study of idarucizumab, and antidote for its blockbuster blood-thinner Pradaxa, …
Anti-blood clotting drug Eliquis gets NICE nod
March 6, 2015Sales and Marketing BMS, DVT, Eliquis, NICE, Pfizer, Pradaxa, apixaban, clotting
Bristol-Myers Squibb and Pfizer’s Eliquis for preventing blood clots has been shown the green light to treat venous thromboembolism (VTE), …
Boehringer chases approval for anti-Pradaxa drug
March 3, 2015Sales and Marketing Boehringer, Boehringer Ingelheim, Pradaxa, bleeding, dabigatran etexilate, idarucizumab
Boehringer Ingelheim is launching new drug applications for its investigational treatment to reverse the effects of its blood-thinning drug Pradaxa. …
Daiichi-Sankyo blood drug gets FDA nod
January 12, 2015Sales and Marketing BMS, Daiichi Sankyo, Daiichi-Sankyo, FDA, Pfizer, Pradaxa, atrial fibrillation, blood, savaysa
The US Food and Drug Administration has shown Daiichi-Sankyo’s anti-clotting drug Savaysa the green light to reduce the risk of …
Boehringer gets NICE nod for Pradaxa
December 16, 2014Sales and Marketing Boehringer, NHS, NICE, Pradaxa, VTE, dagibatran, ingelheim, warfarin
NICE has confirmed a recommendation for Boehringer Ingelheim’s controversial anti-blood clotting drug Pradaxa, as a treatment for blood clots in …
Boehringer trials Pradaxa anti-bleeding antidote
December 11, 2014Sales and Marketing BMS, Bayer, Boehringer, Eliquis, Pradaxa, ash, dabigatran, idarucizumab
Boehringer Ingelheim says that its investigational drug can safely reverse the blood-thinning effect of its anti-clotting drug Pradaxa (dabigatran). The …
NICE recommends new indication for troubled Pradaxa
October 31, 2014Sales and Marketing Boehringer, NHS, NICE, Pradaxa, dabigatran, ingelheim, warfarin
NICE has recommended Boehringer Ingelheim’s controversial anti-blood clotting drug Pradaxa for treating and preventing potentially-fatal blood clots in the legs …
Pfizer/BMS blood thinner gains new licence
August 22, 2014Sales and Marketing BMS, DVT, Eliquis, Pfizer, Pradaxa, Xarelto, blood, warfarin
Pfizer and Bristol-Myers Squibb have been handed a much-needed lift after its new blood thinner Eliquis gained a licence extension …
Pradaxa ‘safe’ says Australian regulator
August 6, 2014Research and Development, Sales and Marketing AF, Australia, BMJ, Pradaxa, stroke
Australia’s drug regulator says it will not be updating its safety advice for Boehringer’s Pradaxa despite mounting safety issues around …
BMJ investigation raises new concerns over Pradaxa
July 24, 2014Medical Communications, Research and Development, Sales and Marketing BMJ, Boehringer, Channel 4, Pradaxa, blood, warfarin
An investigation by The BMJ has raised fresh concerns about Boehringer’s top-selling blood thinner Pradaxa (dabigatran) and the regulatory decisions …
Pradaxa gets DVT indication
June 6, 2014Sales and Marketing Boehringer, DVT, Pradaxa, blood, dabigatran etexilate, thinner
Pradaxa has been given approval in Europe to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) just a week …
Boehringer settles US lawsuits
May 29, 2014Medical Communications, Sales and Marketing Boehringer, Pradaxa, US, blood, lawsuits, warfarin
Boehringer Ingelheim has sought to bring to an end around 4,000 legal cases which have been brought against the company …
Boehringer in hot water over Pradaxa risks
February 19, 2014Sales and Marketing Boehringer, Pradaxa, Xarelto, dabigatran, lawsuit
Boehringer Ingelheim attempted to delay and revise the publication of important drug information surrounding its new anticoagulant Pradaxa. This is …
